1-Bromo-2,5-bis(methoxymethoxy)-3,4,6-trimethylbenzol | 39055-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Bromo-2,5-bis(methoxymethoxy)-3,4,6-trimethylbenzol
• 英文别名: 1-bromo-2,5-bis(methoxymethoxy)-3,4,6-trimethylbenzene
• CAS: 39055-39-5
• 化学式: C₁₃H₁₉BrO₄
• 分子量: 319.195
• InChiKey: NGIACJOMDQFKDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Bromo-2,5-bis(methoxymethoxy)-3,4,6-trimethylbenzol 生成
  参考文献：
  名称：

  HUBSCHER, JOSEF;BARNER, RICHARD, HELV. CHIM. ACTA , 73,(1990) N, C. 1068-1086

  摘要：

  DOI：
• 作为产物：
  描述：

  Bromotrimethylhydrochinon 、 氯甲基甲基醚 在 sodium hydride 作用下， 生成 1-Bromo-2,5-bis(methoxymethoxy)-3,4,6-trimethylbenzol
  参考文献：
  名称：

  总合成vonnatülichemα-生育酚。5. Mitteilung。对称性和环氧不对称性（R）-变色法和C（2）色度系统† ‡

  摘要：

  天然存在的α-生育酚的全合成。不对称的烷基化和不对称的环氧化作为引入（R）-配置在色度部分C（2）的手段

  DOI：

  10.1002/hlca.19900730431

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE MITOCHONDRIALE, NOTAMMENT L'ATAXIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2021202986A1

  公开（公告）日：2021-10-07

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

  该披露提供了治疗化合物、组合物（例如治疗剂或药物）和方法，用于预防或治疗哺乳动物主体中的线粒体疾病，如弗里德赖希共济失调，减少与线粒体疾病（例如弗里德赖希共济失调）相关的风险因素、症状和/或症状，并/或减少线粒体疾病（例如弗里德赖希共济失调）的发生可能性或严重程度。该披露还提供了用于生产上述治疗组合物的新型中间体。在某些情况下，这些中间体本身可能是治疗剂或治疗剂的前药（例如治疗化合物的还原形式）。
• A New Efficient Method for the Preparation of Sulfone-Functionalized Prenylhydroquinones
  作者：Yoshiji Fujita、Michihiro Ishiguro、Takashi Onishi、Takashi Nishida

  DOI：10.1055/s-1981-29490

  日期：——
• FUJITA YOSHIJI; ISHIGURO MICHIHIRO; ONISHI TAKASHI; NISHIDA TAKASHI, SYNTHESIS (BRD), 1981, NO 6, 469-471
  作者：FUJITA YOSHIJI、 ISHIGURO MICHIHIRO、 ONISHI TAKASHI、 NISHIDA TAKASHI

  DOI：——

  日期：——
• XAMAMURA, KITISABURO;AKASAKA, KODZO;YAMAGISI, JODZI
  作者：XAMAMURA, KITISABURO、AKASAKA, KODZO、YAMAGISI, JODZI

  DOI：——

  日期：——
• COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA
  申请人：Stealth BioTherapeutics Corp

  公开号：US20210317146A1

  公开（公告）日：2021-10-14

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

表征谱图